Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma (NCT02224729), a na phase 2 study. The primary outcome is Count of Participants That Experience Overall Response Following 4 Cycles of the Combination Regimen BBd.

2. Clinical Question

3. Trial Design

This was a Phase II, single-group study of bendamustine, bortezomib, and dexamethasone for patients with newly diagnosed multiple myeloma. The registry record lists 24 participants enrolled and the study status as completed. Its start date was 2014-08-25, and its primary completion date was 2016-04-21.

The design has no randomized control arm: allocation is recorded as not applicable, the model as single group, and masking as none. Therefore, the study is a treatment-regimen evaluation within one group, not a like-for-like comparison between assigned interventions. Its results cannot establish a comparative treatment effect against another regimen from this design alone.

The listed treatment schedule specifies bendamustine hydrochloride intravenously over 30 minutes on days 1 and 2; bortezomib subcutaneously on days 1, 8, 15, and 22; and dexamethasone orally on days 1, 8, 15, and 22. Treatment repeats every 35 days for 4 courses if disease progression or unacceptable toxicity does not occur. The arm description is incomplete after a reference to participants achieving less; the further treatment details are not reported in the registry record.

The main efficacy outcome is the count of participants with overall response after 4 cycles. The record also lists adverse events, very good partial remission, progression-free survival, and overall survival as secondary outcomes. These outcome listings do not, by themselves, establish that numerical results were posted for each measure.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: 4 subjects were not evaluable - (1 didn't get any therapy on study, 1 received only first cycle and 2 developed medical issues that took them off study during the first cycle)

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Count of Participants That Experience Overall Response Following 4 Cycles of the Combination Regimen BBd, measured over At least 140 days.

The primary endpoint is the count of participants experiencing overall response following 4 cycles of the BBd combination regimen. The registry defines overall response as partial remission or better after induction therapy. The recorded timeframe is at least 140 days.

As a count endpoint, it describes how many participants met the response definition in the study group. It does not directly provide a comparison with another treatment, and it is not a measure of how long response lasted. The response count and a corresponding estimate of the response proportion are not reported in the registry record, so the primary endpoint cannot be interpreted numerically from this record.

General statistical context: response is a binary outcome for each participant—either the response criterion is met or it is not. A count can be useful for describing observed outcomes, but its interpretation depends on knowing which participants were included in the assessment and how unevaluable or missing outcomes were handled. The record identifies 4 participants as not evaluable and gives reasons, but does not report a complete analysis-population definition or the method used to handle those participants in the primary endpoint.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record identifies the study as Phase II and single group, with no masking. It does not report a statistical analysis plan, and no analyses are listed. Accordingly, there is no reported inferential procedure to describe as the sponsor’s primary method for evaluating the response endpoint.

What a count endpoint describes

The primary outcome is a count of participants who experienced overall response after 4 cycles. General statistical explanation: when each participant is classified as meeting or not meeting a response definition, the count summarizes the number meeting it in the assessed group. A count alone does not communicate the size of the assessed group or the uncertainty around a response proportion. Those details are especially important when some enrolled participants are not evaluable.

The endpoint definition is partial remission or better following induction therapy. The registry record identifies 4 participants as not evaluable and gives reasons, but it does not state whether they were excluded from the primary analysis, treated as nonresponders, or handled in another way. It also does not provide a response count. Thus, neither a response proportion nor a confidence interval can be reconstructed from the record.

What uncertainty measures would mean

General statistical explanation: a confidence interval describes a range of values compatible with the observed data under a specified statistical method. It conveys uncertainty in an estimate; it does not guarantee that the true value lies within the interval. For a response proportion, the interval’s width depends in part on the number assessed and the observed response count. Since those primary-result details are not reported, the precision of the response estimate cannot be evaluated.

A p-value, when used, addresses how compatible the observed data are with a stated null hypothesis under the model used. A p-value is not a measure of the probability that a treatment works, nor does it quantify the size or clinical importance of an effect. No p-value or hypothesis test for the primary outcome is reported in the registry record. There is also no randomized comparison arm against which a treatment contrast could be tested.

Single-group design and interpretation

General statistical explanation: a single-group study can describe outcomes observed among participants receiving a regimen, but it does not itself provide a concurrent estimate of what would have happened to similar participants under another regimen. In a randomized trial, random assignment can support a comparison between groups by balancing measured and unmeasured factors on average. This study has no randomized comparison; its allocation is recorded as not applicable. Any response result would therefore be descriptive of the study group rather than a randomized comparative effect.

The absence of masking is also part of the design description. The record does not state whether outcome assessment was independently reviewed or blinded by another process. Such details are not reported in the registry record and should not be presumed.

Planning assumptions are not trial results

The planning illustration is described as using a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the effect to detect defined as a stated fraction of the observed effect. It is explicitly a planning illustration based on an observed effect, not the trial’s own design. Its two-arm assumptions do not match this single-group study, so they should not be read as the study’s allocation plan or as evidence that a randomized comparison occurred.

General statistical explanation: sample-size planning estimates how many participants a future study might need under chosen assumptions about the effect, variability, significance threshold, power, and design. Such calculations are prospective planning tools. They do not show that the completed study had a particular probability of detecting an effect, and they are not observed power. The registry record does not report the original sample-size justification or a protocol-based statistical plan. No numerical planning outputs are available in the record.

Time-to-event outcomes

Progression-free survival and overall survival are listed as secondary outcomes. General statistical explanation: time-to-event analysis uses both event status and the time until an event or censoring, rather than treating every participant as having the same follow-up. A method such as a survival curve can describe the event experience over time, while a comparison method can evaluate differences between groups when an appropriate comparison exists. The record does not report the time-to-event estimates, follow-up details, censoring rules, or analyses for these outcomes. A count of participants experiencing an outcome, without those details, is not enough to reconstruct a time-to-event analysis.

Over-dispersion is a general concern when count data vary more than a chosen model expects. It is not possible to assess that issue from this primary endpoint as recorded, because the endpoint is a participant count and no model or numerical response results are reported. No model choice or adjustment method should be inferred from the endpoint label alone.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Bendamustine, Bortezomib, Dexamethasone (Standard)")
n      <- c(20)
events <- c(13)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Bendamustine, Bortezomib, Dexamethasone (Standard)  20  13  65.0  40.8  84.6  43.3  81.9  43.0  81.9

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists one primary outcome and several secondary outcomes: serious adverse events, very good partial remission, progression-free survival, and overall survival. It does not report a multiplicity strategy, such as a hierarchy of tests, an adjustment across outcomes, or a distinction between confirmatory and exploratory testing. Without such information, the statistical interpretation of any multiple outcome tests cannot be established from the record.

No statistical analyses are listed. The record does not report a formal analysis plan, primary hypothesis test, confidence interval method, or prespecified handling of missing data. The sample-size justification and planned analysis population are also not reported in the registry record.

The primary outcome description states that 4 participants were not evaluable. One did not receive study therapy, one received only the first cycle, and two developed medical issues that took them off study during the first cycle. These statements explain why they were not evaluable, but do not establish how their outcomes were handled in an analysis. The record does not specify whether analysis was based on all enrolled participants, participants who received treatment, or another population.

General statistical explanation: missing-data handling can affect an estimate when participants without outcome assessments differ from those with assessments. Excluding participants, assigning an outcome, or using a model each relies on assumptions, and these approaches can produce different results. Without a stated rule and the outcome count, the effect of the 4 non-evaluable participants on the primary result cannot be assessed.

The record also does not state whether there were interim analyses or stopping rules. Neither should be inferred from the study’s completion status or the reported treatment schedule.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: joint function pain (4.2%), death- anaphylactic shock (4.2%), hypercalcemia (4.2%), gout (4.2%), syncope episode (4.2%).

The adverse-event record lists 24 participants at risk for serious adverse events, with 9 affected. It also lists 24 participants at risk for other adverse events, with 24 affected. The registry records 1 death. These are counts for this single study group, not comparisons between treatments.

The listed serious adverse-event terms are Joint Function Pain, Death- Anaphylactic Shock, Hypercalcemia, Gout, Syncope episode, and Febrile Neutropenia. Each term is reported with a frequency of 4.2%. These term-level frequencies should be read as registry-reported figures; the record does not provide further detail about event timing, duration, recurrence, or the number of events per affected participant. The death count and the listed death-related term should not be combined or interpreted beyond what the registry reports.

General statistical explanation: an adverse-event count describes what was recorded among people followed in the study. It does not, by itself, establish that the regimen caused an event, and a single-group study cannot estimate a comparative safety difference against another treatment. The record does not report an exposure-adjusted event rate or a comparative safety analysis.

13. What the Result Does, and Does Not, Mean

The registry record establishes that a Phase II study of bendamustine, bortezomib, and dexamethasone was completed in a single group of 24 participants with newly diagnosed multiple myeloma. It identifies overall response after 4 cycles as the primary outcome and defines response as partial remission or better. It also documents that 4 participants were not evaluable and gives reasons for that status.

What the record does not establish is the observed primary response result. No primary response count is reported, and there is no response estimate or confidence interval in the available information. The registry record therefore does not allow a numerical assessment of how many participants met the endpoint or how precisely that outcome was estimated.

The design also does not establish a comparative treatment effect. There is no control group, and the study is not described as randomized. Even if a response count were available, outcomes in this single group would not show how the regimen compares with another therapy under the same study conditions.

Safety figures are descriptive: the record lists 9 participants with serious adverse events, 24 with other adverse events, and 1 death. The listed serious-event terms each have a reported frequency of 4.2%. These observations do not establish comparative risk or causal attribution.

General statistical context: evidence from a clinical study is interpreted by considering the endpoint definition, design, analysis population, observed estimate, and its uncertainty together. Here, design and selected safety details are reported, but the primary response result and its analysis details are not. No conclusion about treatment benefit or lack of benefit follows from the absence of a result in the registry record.

14. Why This Trial Matters Statistically

This study is statistically notable for the contrast between a clearly identified primary endpoint and the absence of its numerical result in the registry record. The endpoint is defined as a count of participants achieving partial remission or better after 4 cycles, and the timeframe is given as at least 140 days. Yet without the response count and analysis denominator, readers cannot quantify the observed response outcome or evaluate its precision.

The study design is equally important to interpretation. It is a single-group Phase II study with no masking and no randomized comparator. That design can describe outcomes observed among treated participants, but it cannot provide a randomized estimate of how the regimen performs relative to another treatment. Recognizing this distinction prevents a within-group observation from being mistaken for a comparative treatment effect.

The record also identifies 4 participants as not evaluable for stated reasons. Reporting these reasons is useful, but the analysis rules for these participants are not reported. This illustrates why outcome results require a clear account of who contributed to the analysis and how unavailable outcomes were handled.

Finally, safety counts and listed serious-event terms offer descriptive information, while the lack of a comparative group limits conclusions about relative safety. Overall, the statistical value of the record lies in its description of the study structure, endpoint, and selected safety counts, alongside the important limits created by absent efficacy results and unreported analysis details.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation for interpreting efficacy is that the registry record does not report the primary response count. It therefore provides no observed response estimate, confidence interval, or primary endpoint test. The endpoint is described, but its numerical result cannot be assessed.

The study has no comparator group and is not randomized. This prevents a like-for-like comparison with another regimen and limits interpretation to description of the study group. The absence of masking is recorded, but the record does not state whether response assessment used independent or blinded review.

Four participants were not evaluable, with reasons given, but the record does not explain their treatment in the primary analysis or define the analysis population. It also does not report the original sample-size justification, a statistical analysis plan, multiplicity handling, interim analyses, or stopping rules. These omissions make it difficult to assess whether analyses followed prespecified methods.

Secondary outcomes are listed, but numerical findings and analysis details are not reported in the available registry record. For progression-free survival and overall survival, the record does not provide estimates, follow-up information, or censoring rules. For adverse events, counts and selected terms are reported, but event timing and further clinical detail are not included in the registry entries.

The treatment description is incomplete after a reference to participants achieving less, so additional regimen details are not reported in the registry record. The planning assumptions described for a two-arm illustration do not represent this single-group design and should not be treated as the study’s own design or as observed power.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma — NCT02224729.
• Registry record last updated 2025-04-30; status last verified 2025-04.
• Results first posted 2018-06-07.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT02224729 is a completed Phase II, single-group study of bendamustine hydrochloride, bortezomib, and dexamethasone in newly diagnosed multiple myeloma. The registry lists 24 participants enrolled, no masking, and no randomized comparator.

The primary outcome is the count of participants with overall response—partial remission or better—following 4 cycles, with a timeframe of at least 140 days. The primary response count is not reported in the registry record. Four participants were described as not evaluable, with reasons listed.

Safety information includes 9 participants affected by serious adverse events, 24 affected by other adverse events, and 1 death. The record does not list statistical analyses or a statistical analysis plan. As a result, efficacy findings and their precision cannot be evaluated from the reported information.